Evidence map›Paper›PMID 34050331›Full record

ReviewNature reviews. Neurology2021

Fundamental mechanistic insights from rare but paradigmatic neuroimmunological diseases.

Heinz Wiendl, Catharina C Gross, Jan Bauer, Doron Merkler, Alexandre Prat, Roland Liblau

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Heinz Wiendl *Department of Neurology with Institute of Translational Neurology, University and University Hospital Münster, Münster, Germany. wiendl@uni-muenster.de.ORCID http://orcid.org/0000-0003-4310-3432
Catharina C Gross *Department of Neurology with Institute of Translational Neurology, University and University Hospital Münster, Münster, Germany.ORCID http://orcid.org/0000-0002-4872-9189
Jan BauerDepartment of Neuroimmunology, Center for Brain Research, Medical University of Vienna, Vienna, Austria.ORCID http://orcid.org/0000-0001-5802-8047
Doron MerklerDepartment of Pathology and Immunology, Division of Clinical Pathology, University and University Hospitals of Geneva, Geneva, Switzerland.
Alexandre PratDepartment of Neuroscience, University of Montreal, Montreal, Canada.
Roland LiblauInfinity, Université Toulouse, CNRS, Inserm, Toulouse, France.ORCID http://orcid.org/0000-0001-5477-5475

Funding

Austrian Science Fund FWF P 26936
6 · The paper itself

Abstract

The pathophysiology of complex neuroimmunological diseases, such as multiple sclerosis and autoimmune encephalitis, remains puzzling - various mechanisms that are difficult to dissect seem to contribute, hampering the understanding of the processes involved. Some rare neuroimmunological diseases are easier to study because their presentation and pathogenesis are more homogeneous. The investigation of these diseases can provide fundamental insights into neuroimmunological pathomechanisms that can in turn be applied to more complex diseases. In this Review, we summarize key mechanistic insights into three such rare but paradigmatic neuroimmunological diseases - Susac syndrome, Rasmussen encephalitis and narcolepsy type 1 - and consider the implications of these insights for the study of other neuroimmunological diseases. In these diseases, the combination of findings in humans, different modalities of investigation and animal models has enabled the triangulation of evidence to validate and consolidate the pathomechanistic features and to develop diagnostic and therapeutic strategies; this approach has provided insights that are directly relevant to other neuroimmunological diseases and applicable in other contexts. We also outline how next-generation technologies and refined animal models can further improve our understanding of pathomechanisms, including cell-specific and antigen-specific CNS immune responses, thereby paving the way for the development of targeted therapeutic approaches.

Indexed as

AnimalsHumansImmune System DiseasesNervous System DiseasesNeuroimmunomodulationRare DiseasesSusac Syndrome

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.